December 14, 2009

Interleukin-2 Receptor Antibody Reduces Rejection Rates and Graft Loss in Live-Donor Kidney Transplant Recipients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

This registry analysis found that compared to no antibody therapy, living-donor recipients who received IL-2 receptor antibody treatment at the
time of transplant were at lower risk for acute rejection. At 5 years, IL-2 receptor antibody was also associated with a lower risk of overall graft failure at 5 years, and better renal function at 1 year, although not at 3 years.

Renal Transplantation